Synergism of PDL/PD1 and IL33/ST2 Axis in Tumor Immunology

Abstract

When it comes to tumor immunology, understanding of molecular pathways is rather important. During oncogenesis, many molecules should be taken in consideration altogether in context of a single malignancy. It is of a great significance to determine whether these molecules act synergistically or contrary, whether to understand a malignant disease more thoroughly, or even more important, to reveal new approaches of therapy. In this review, we discuss whether and how IL-33/ST2 and PD-1/PDL axis involve in antitumor immunity.

SUMOylated IL-33 in the nucleus stabilizes the transcription factor IRF1 in hepatocellular carcinoma cells to promote immune escape

“…In a review of the role of IL-33 and PD-L1 signaling in antitumor immunity, Jovanovic et al. ( 36 ) suggest that the relationship between IL-33 and PD-L1 is unclear. We reported that nuclear factor IL-33 negatively regulated PD-L1 expression in HCC cells, making them more sensitive to T cell responses.…”

Metformin as a Potential Antitumor Agent

“…One of the ways in which metformin influences immune responses to cancer is by modulating the expression of the programmed death ligand (PD-L1, also known as CD274 or B7-H1) (60). Studies have shown that molecule PD-L1 is expressed at significantly higher levels in various cancer types in which it promotes cell proliferation, migration and invasion while the other studies showed that PD-1 can have immunomodulatory effect (61)(62)(63)(64). Role of PD-L1 is to provide an inhibitory signal to cytotoxic T lymphocytes (CTLs) through binding to an inhibitory PD-1 receptors on activated CTLs.…”